Drug Trial Radar · NCT01082302
Pharmacokinetic Study of Topically Applied Veregen 15% Compared With Oral Intake of Green Tea Beverage
Last checked: Nov 19, 2026Latest source record: Sep 8, 2010 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
43
Actual
Start
Jan 2010
Primary completion
Aug 2010
Study completion Aug 2010
Sponsor
- Lead sponsor
- MediGeneIndustry
- Sponsor type
- Industry
- Collaborators
- Charité Research Organisation GmbH
- First posted
- Mar 8, 2010
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This open, monocentric study is designed to investigate plasma concentrations of certain catechins after topical application of Veregen 15% ointment to genital or perianal warts in comparison to catechin plasma concentrations after oral intake of a defined dose of green tea beverage. The study is intended to demonstrate that topical administration of Veregen 15% induces catechin plasma concentrations lower or equivalent to those that can be reached with normal consumption of green tea.
Conditions
- Genital Warts
- Perianal Warts
Interventions
Polyphenon E (Veregen) 15% ointmentDrug
3 times daily application on genital and perianal warts over 7 days
Green Tea Beverage with defined catechin contentOther
3 times daily oral intake over 7 days
Primary outcomes
What the sponsor says the trial is designed to measure.
- Pharmacokinetic profile of green tea catechinsTime frame: Day 1/2 and Day 7/8
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Charité Research Organisation
Berlin, Germany
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.